{"id":410464,"date":"2021-01-07T09:03:44","date_gmt":"2021-01-07T14:03:44","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=410464"},"modified":"2021-01-07T09:03:44","modified_gmt":"2021-01-07T14:03:44","slug":"invo-bioscience-management-letter-to-shareholders","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/invo-bioscience-management-letter-to-shareholders\/","title":{"rendered":"INVO Bioscience Management Letter to Shareholders"},"content":{"rendered":"
\n

Key Developments and Future Initiatives Position INVOcell\u00ae Within the Severely Underserved Fertility Market<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SARASOTA, Fla.<\/span>, Jan. 7, 2021<\/span> \/PRNewswire\/ —\u00a0INVO Bioscience, Inc.<\/b> (NASDAQ: INVO) (“Company”) (‘INVO”), <\/b>a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System, INVOcell\u00ae, an effective and affordable treatment for patients diagnosed with infertility, is pleased to provide a year-end letter to shareholders.<\/p>\n

\n

\n
\n \"INVO
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Dear Shareholders,<\/p>\n

As we begin the 2021 calendar year, we wanted to take the opportunity to wish you all a Happy New Year and to provide a brief summary of our recent progress at INVO, which we feel has been transformative to the business. We would also like to provide an outline of our key initiatives moving forward.\u00a0 <\/p>\n

It goes without saying that 2020 was truly a unique year. The COVID-19 pandemic negatively impacted the entire world economically, physically, and psychologically. We are optimistic that as new treatment modalities and vaccines come to market that we can begin to return to some sense of normalcy throughout 2021. <\/p>\n

Similar to many other medical device companies that support discretionary procedures and treatments, our commercialization efforts and the general pace of INVOcell’s market adoption was certainly impacted during 2020, both with our internal efforts and our key partnering activities. However, we believe our overall market opportunity was not impacted as we believe INVOcell is well suited to address existing lab capacity challenges and provide an affordable and efficacious fertility option for patients in need.<\/p>\n

Various market estimates suggest that the current Global Fertility market exceeds $20 billion<\/span> and is growing, yet it remains severely underserved, with nearly 95% of couples in need of infertility treatment going without care.\u00a0High costs relative to success, limited access to treatment in many areas, existing lab capacity issues, as well as cultural and religious factors are all contributors to this significant underserved market.\u00a0 <\/p>\n

The underserved market is the real opportunity for INVOcell. We believe the value proposition of INVOcell\u00a0as an affordable and efficient treatment technology\u00a0with reduced infrastructure requirements can expand capacity and access to care, allowing us to increase adoption as patients look for alternative and effective solutions with strong clinical outcomes. <\/p>\n

\n Transformative Accomplishments<\/b>\n <\/p>\n

We believe the Company’s progress over the past 18-24 months has proven to be transformational and has positioned us well for future market expansion. These highlighted accomplishments include the following: <\/p>\n